The Texas Chiropractic Association (TCA) Recognizes Parker University and Several Alumni at Chiro Texpo 2025
Dallas, Texas, July 11, 2025 (GLOBE NEWSWIRE) — The Texas Chiropractic Association (TCA) recently recognized chiropractic leaders during Chiro Texpo 2025, the annual state chiropractic convention, which was held at the Hyatt Regency Frisco-Dallas in Frisco.
TCA is the voice for chiropractic in Texas, providing protection, state-wide advocacy, information, and education for more than 7,000 DCs who are licensed to practice in Texas. TCA advocates the position that citizens of Texas should have adequate access to the healthcare of their choice and that DCs are adequately represented in the government's decision-making process.
Awards were presented to Texas chiropractors and other chiropractic supporters at the President's Gala, with Parker University alumni walking away with awards from key categories.
Parker University Chiro Texpo 2025 Honorees: Young Chiropractor of the Year – Korey Rose, DC
President's Award – Jon Blackwell, DC, and Korey Rose, DC
Executive Director's Award – Steve Van Osdale, DC
Regional Doctor of the Year – Region 1: Kaci Roach, DC, Region 2: Joseph Adams, DC
Texas Women's Leadership and Service Award – Mary Collings, DC, and Clare Morgan, DC
Student Leadership Award – Parker University Tri 9 student Hayden Hadley
During Chiro Texpo 2025, TCA also announced and swore in its new executive officers for the 2025-2026 term, all of whom are Parker University graduates! TCA's executive officers preside over an executive committee, including four department coordinators in charge of TCA's state committees, as well as a board of directors comprised of representatives from TCA's 12 districts, which cover all of Texas.
TCA's New Executive Officers for 2025-2026: Don White, DC, FICC – president
Andrew Oteo, DC – vice president
Korey Rose, DC – secretary/treasurer
Todd Whitehead, DC (served as TCA's president in 2024-2025) – immediate past president
Congratulations to all the leaders who were recognized and honored for their dedication to furthering the positive impact of chiropractic care in the state of Texas.
About Parker University
Parker University, the fastest-growing college in Dallas and the fourth-fastest-growing in Texas, was founded in 1982 by Dr. James William Parker as Parker College of Chiropractic. Today, the university serves over 2,300 students and offers more than 25 accredited academic programs and certificates, including its flagship Doctor of Chiropractic program, which is home to the second-largest chiropractic cohort in the world. Parker University also leads in innovation with master's degrees in Clinical Neuroscience, Strength and Human Performance, and Functional Nutrition. Additionally, five new board-approved programs are set to launch soon.
Attachment The Texas Chiropractic Association (TCA) Recognizes Parker University and Several Alumni at Chiro Texpo 2025.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
14 hours ago
- Business Upturn
KIF18A Targeting Therapies FDA EMA Approval Clinical Trials By Indication Company Country Drug Class Report
Delhi, July 12, 2025 (GLOBE NEWSWIRE) — Global KIF18A Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025 Report Highlights & Findings: First KIF18A Targeting Therapy Commercial Availability Expected By 2030 Highest Phase Of Development: Phase-I/II KIF18A Targeting Therapies In Clinical Trials: > 10 Therapies KIF18A Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase KIF18A Targeting Therapies Market Development Trends Insight KIF18A Therapies Technology Platforms Insight Download Report: The global KIF18A targeting therapies market is rapidly gathering momentum as KIF18A has emerged as a key vulnerability in cancers characterized by chromosomal instability. As a mitotic kinesin motor protein essential for chromosome alignment during cell division, KIF18A is overexpressed in malignancies such as ovarian and triple-negative breast cancers, making it a promising target for precision oncology with potentially lower toxicity than traditional chemotherapies. Although no KIF18A-targeted therapy is commercially available yet, the field is progressing quickly. Clinical pipelines include more than 10 therapies, with several in early clinical development. Among the frontrunners is ATX‑295 from Accent Therapeutics, an oral, best-in-class small-molecule inhibitor that recently entered a Phase I/II dose-escalation study in patients with advanced solid tumors, including ovarian and triple-negative breast cancer. It's employed with biomarker-enriched enrollment based on genomic instability markers like whole-genome doubling, and has received FDA Fast Track status—accelerating its path forward. The clinical landscape includes global contributions from leading biotechs such as Volastra Therapeutics, advancing multiple small-molecule inhibitors including Sovilnesib (AMG‑650) in Phase I for platinum-resistant ovarian cancer, and VLS‑1488 in Phase I/II across chromosomal instability-high tumors. Accent's ATX‑295 stands currently at the most advanced Phase I/II stage, with trials in the US and potentially Asia-Pacific, suggesting geographic development convergence. Technological innovation underpins expansion in this field. Development is dominated by small-molecule inhibitors designed to halt KIF18A's motor activity at kinetochores, causing mitotic catastrophe in cancer cells. Alternative approaches include disrupting upstream regulatory pathways like phosphorylation, and leveraging AI-driven drug discovery platforms. For example, Insilico Medicine's Chemistry42 and PandaOmics platforms generated a macrocyclic KIF18A inhibitor (ISM9682), showcasing the power of AI to enhance specificity and efficiency in drug design. Market trends demonstrate strong growth potential. The first commercial KIF18A-targeting therapy is expected by 2030, propelled by fast track designations and positive preclinical data. The rich pipeline, combined with precision biomarker strategies, supports a robust developmental roadmap, aligning with unmet clinical needs in CIN-high solid tumors and potentially extending to hematologic malignancies where KIF18A overexpression correlates with poor prognosis. Regional development trends show clinical leadership based in the US and Europe, where companies like Accent and Volastra are active, while China and other Asia-Pacific markets are engaging through global trial participation and local biotech collaborations. Multi-region trial footprints and biomarker-defined patient enrollment strategies are shaping global development dynamics. Our Global KIF18A Targeting Therapies Market Report offers detailed insights into this evolving therapeutic area. It profiles more than ten clinical-stage candidates by company, indication, country, and development phase, with a deep focus on ATX‑295 as the leading Phase I/II program. The report evaluates technology platforms, including small-molecule motor inhibitors and AI-enabled discovery, and analyzes biomarker-led patient selection models. Regional development trends and regulatory environments are mapped, and strategic partnerships and investments are examined. For pharmaceutical executives, biotech investors, and drug development leaders, this report provides a strategic foundation. It outlines market drivers, technological innovations, and clinical milestones that are poised to transform KIF18A from a promising target into an approved therapeutic by 2030, potentially offering new treatment options for patients with chromosomally unstable tumors. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
14 hours ago
- Business Upturn
Dr. Anosh Ahmed Foundation Announces Aid for Texas Flood Victims Through America First Foundation
Chicago, IL, July 12, 2025 (GLOBE NEWSWIRE) — In response to the recent floods impacting communities across Texas, Dr. Anosh Ahmed, physician and founder of the Anosh Supports America First Foundation, has announced a relief initiative aimed at assisting affected families. The initiative will include direct financial assistance, support for grieving families, and home reconstruction efforts for uninsured residents Standing with Texas As rising waters displace thousands across the state, Dr. Anosh Ahmed has activated his foundation's emergency response team to work with local authorities and communities hardest hit by the disaster. His support will focus on: Direct financial assistance to families who have lost loved ones to families who have lost loved ones Shelter and essential supplies for displaced residents for displaced residents Home rebuilding assistance for uninsured families for uninsured families Collaboration with churches, community organizations, and first responders to ensure effective outreach 'When Americans suffer, we don't wait — we act,' said Dr. Anosh Ahmed. 'This is not just about recovery. It's about restoring dignity and security for our fellow citizens.' America First in Action Founded earlier this year, the Anosh Supports America First Foundation was created to uphold and support the pillars of American strength — the military, law enforcement including members of Department of Justice and ex-FBI agents and their families, first responders, and patriotic communities. Dr. Anosh Ahmed's latest move expands that mission into disaster relief, reinforcing his belief that helping those in need is one of the most American acts of all. 'Being a proud Republican and believer in America First means stepping up when our people need help — not just with words, but with real action,' he added. Rebuilding Lives, Not Just Structures Dr. Anosh Ahmed's Texas relief plan includes long-term support beyond the initial recovery. His foundation will: Fund home reconstruction for uninsured families Provide mental health and grief counseling resources Support first responders and veterans affected by the disaster Launch community rebuilding initiatives focused on resilience and preparedness A special 'Texas Strong: America First Gala' will be hosted by the foundation in Dallas to raise additional funds and awareness. Supporting Those Who Serve Dr. Ahmed emphasized that veterans, police officers, and military families will be given priority in the foundation's housing and aid programs. His long-standing appreciation for America's protectors is at the heart of every initiative he undertakes. 'Our heroes in uniform deserve more than just our thanks—they deserve action. This relief effort will ensure they are not left behind,' Dr. Anosh Ahmed stated. About Dr. Anosh Ahmed Dr. Anosh Ahmed is a physician, entrepreneur, and Republican philanthropist dedicated to the principles of service, patriotism, and community. Through his Anosh Supports America First Foundation , he works to uplift those who serve and strengthen American communities in times of need. #anoshAhmed #dranoshahmed #anoshahmedMD #dranoshahmedchicago #anoshahmedofficial #anoshIncfoundation #anoshahmedleadership #anoshahmedbook Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
a day ago
- Business Upturn
Clarification on Leadership Announcement: Annette Slyman not to join Life Backup Plan as Chief Operating Officer
Aliso Viejo, CA, July 11, 2025 (GLOBE NEWSWIRE) — Galacxia, Inc., the developer of the Life Backup Plan app, is issuing a clarification to our July 10, 2025 press release. Annette Slyman will not be joining the team in any capacity, due to extenuating circumstances. Plans evolve. Our mission stays the course. We continue to hold Ms. Slyman in the highest regard. Galacxia remains committed to delivering innovative digital health and safety solutions that improve lives and support communities nationwide. About Life Backup Plan by Galacxia, Inc. Life Backup Plan is an end-to-end safety, emergency detection, digital health and multi-faceted care app that reduces tragedies, improves outcomes, lowers medical costs, and eases the burden on families and the healthcare system. Unlike other health and personal safety systems that require pressing a button to summon help, Life Backup Plan proactively checks on people, shares critical health data, coordinates support, and handles everything from emergency response to long-term caregiving, end-of-life planning, and daily logistics. We're delivering a comprehensive solution that bridges fragmented systems, supports value-based care, and brings modern tools into a system still largely reliant on fax machines.. Galacxia, Inc. is a SBA certified Woman-Owned Small Business and Delaware C Corporation committed to transforming personal safety, emergency response, and health access and equity. Eyes on the stars. Hands on the wheel. Heart in the mission. Press inquiries Life Backup Plan by Galacxia, Inc Sandy Eulitt [email protected] 8588480860 49 El Prado Lane, Oceanside, CA 92058
